M&A Deal Summary

Leinco Acquires QED Biosciences

On September 3, 2024, Leinco acquired life science company QED Biosciences

Acquisition Highlights
  • This is Leinco’s 1st transaction in the Life Science sector.
  • This is Leinco’s 1st transaction in the United States.
  • This is Leinco’s 1st transaction in California.

M&A Deal Summary
Date 2024-09-03
Target QED Biosciences
Sector Life Science
Buyer(s) Leinco
Deal Type Add-on Acquisition

Target

QED Biosciences

San Diego, California, United States
QED Biosciences provides antibodies, kits, and recombinant proteins and antigens catering to the diverse needs of the IVD and research communities. QED Biosciences is based in San Diego, California.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Leinco

St. Louis, Missouri, United States
Category Company
Founded 1992
Sector Life Science
DESCRIPTION

Leinco is a biotechnology company that is engaged in manufacturing of early discovery research products including antibodies, recombinant proteins, ELISA kits, second step reagents, and other life sciences products. Leinco was founded in 1992 and is based in St. Louis, Missouri.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal